company background image
LGND

Ligand Pharmaceuticals NasdaqGM:LGND Stock Report

Last Price

US$69.70

Market Cap

US$1.2b

7D

-2.7%

1Y

-53.4%

Updated

05 Dec, 2022

Data

Company Financials +
LGND fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

LGND Stock Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.

Ligand Pharmaceuticals Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ligand Pharmaceuticals
Historical stock prices
Current Share PriceUS$69.70
52 Week HighUS$164.84
52 Week LowUS$57.77
Beta1.0
1 Month Change12.42%
3 Month Change-22.86%
1 Year Change-53.43%
3 Year Change-34.12%
5 Year Change-48.39%
Change since IPO16.16%

Recent News & Updates

Recent updates

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Oct 21
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt

Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Aug 11
Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%

Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

Jun 27
Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly

We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Mar 17
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Dec 03
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Oct 11
Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Aug 19
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Calculating The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Jun 25
Calculating The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Here's Why Shareholders May Want To Be Cautious With Increasing Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Pay Packet

May 29
Here's Why Shareholders May Want To Be Cautious With Increasing Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Pay Packet

Ligand Pharmaceuticals Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 06
Ligand Pharmaceuticals Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Is Ligand Pharmaceuticals (NASDAQ:LGND) Using Too Much Debt?

May 03
Is Ligand Pharmaceuticals (NASDAQ:LGND) Using Too Much Debt?

Are Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Investors Paying Above The Intrinsic Value?

Mar 04
Are Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Investors Paying Above The Intrinsic Value?

Trade Alert: The Senior VP Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Charles Berkman, Has Sold Some Shares Recently

Feb 06
Trade Alert: The Senior VP Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Charles Berkman, Has Sold Some Shares Recently

Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

Jan 13
Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?

How Should Investors React To Ligand Pharmaceuticals' (NASDAQ:LGND) CEO Pay?

Dec 18
How Should Investors React To Ligand Pharmaceuticals' (NASDAQ:LGND) CEO Pay?

Ligand Pharmaceuticals (NASDAQ:LGND) Share Prices Have Dropped 34% In The Last Three Years

Nov 27
Ligand Pharmaceuticals (NASDAQ:LGND) Share Prices Have Dropped 34% In The Last Three Years

Shareholder Returns

LGNDUS PharmaceuticalsUS Market
7D-2.7%2.4%1.5%
1Y-53.4%15.5%-14.9%

Return vs Industry: LGND underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.

Return vs Market: LGND underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is LGND's price volatile compared to industry and market?
LGND volatility
LGND Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: LGND is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: LGND's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987154John Higginshttps://www.ligand.com

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression.

Ligand Pharmaceuticals Incorporated Fundamentals Summary

How do Ligand Pharmaceuticals's earnings and revenue compare to its market cap?
LGND fundamental statistics
Market CapUS$1.18b
Earnings (TTM)-US$21.29m
Revenue (TTM)US$241.67m

4.9x

P/S Ratio

-55.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LGND income statement (TTM)
RevenueUS$241.67m
Cost of RevenueUS$112.21m
Gross ProfitUS$129.46m
Other ExpensesUS$150.76m
Earnings-US$21.29m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.26
Gross Margin53.57%
Net Profit Margin-8.81%
Debt/Equity Ratio9.4%

How did LGND perform over the long term?

See historical performance and comparison